# Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma

> **NCT01695590** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Prolexys Pharmaceuticals** · enrollment: 40 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** PRLX 93936

## Key facts

- **NCT ID:** NCT01695590
- **Lead sponsor:** Prolexys Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-03
- **Primary completion:** 2014-03
- **Final completion:** 2014-09
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2013-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01695590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01695590, "Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01695590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*